MX364312B - Composición que comprende al menos dos moléculas neutralizadoras-aglutinadoras del virus de influenza a. - Google Patents
Composición que comprende al menos dos moléculas neutralizadoras-aglutinadoras del virus de influenza a.Info
- Publication number
- MX364312B MX364312B MX2015013291A MX2015013291A MX364312B MX 364312 B MX364312 B MX 364312B MX 2015013291 A MX2015013291 A MX 2015013291A MX 2015013291 A MX2015013291 A MX 2015013291A MX 364312 B MX364312 B MX 364312B
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- virus
- composition
- neutralizing
- binding molecules
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 2
- 241000712431 Influenza A virus Species 0.000 abstract 3
- 101710154606 Hemagglutinin Proteins 0.000 abstract 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
- 101710176177 Protein A56 Proteins 0.000 abstract 2
- 239000000185 hemagglutinin Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000037797 influenza A Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130034041 | 2013-03-29 | ||
KR1020130148247A KR20140118682A (ko) | 2013-03-29 | 2013-12-02 | 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물 |
PCT/KR2014/002691 WO2014158001A1 (fr) | 2013-03-29 | 2014-03-28 | Composition comprenant au moins deux molécules de liaison de neutralisation du virus de la grippe a |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015013291A MX2015013291A (es) | 2015-12-15 |
MX364312B true MX364312B (es) | 2019-04-22 |
Family
ID=51991477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013291A MX364312B (es) | 2013-03-29 | 2014-03-28 | Composición que comprende al menos dos moléculas neutralizadoras-aglutinadoras del virus de influenza a. |
Country Status (12)
Country | Link |
---|---|
US (1) | US10703802B2 (fr) |
EP (1) | EP3011968B1 (fr) |
JP (1) | JP6072348B2 (fr) |
KR (3) | KR20140118682A (fr) |
CN (1) | CN105338994B (fr) |
AU (1) | AU2014244668B2 (fr) |
CA (1) | CA2902147C (fr) |
EA (1) | EA030447B1 (fr) |
ES (1) | ES2831802T3 (fr) |
IL (1) | IL241881B (fr) |
MX (1) | MX364312B (fr) |
WO (1) | WO2014158001A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2837392T3 (es) | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
CA2954780A1 (fr) | 2014-07-15 | 2016-01-21 | Medimmune, Llc | Neutralisation d'anticorps anti-grippe b et leurs utilisations |
US20180008702A1 (en) * | 2014-12-05 | 2018-01-11 | Celltrion Inc. | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same |
WO2016089181A1 (fr) * | 2014-12-05 | 2016-06-09 | (주)셀트리온 | Composition d'adjuvant contenant au moins une molécule liant au virus de la grippe et neutralisant ce dernier et composition vaccinale contenant cette molécule |
TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
AU2016271323B2 (en) | 2015-06-01 | 2022-08-25 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
CN116271017A (zh) | 2016-01-13 | 2023-06-23 | 免疫医疗有限责任公司 | 治疗甲型流感的方法 |
JP6800591B2 (ja) * | 2016-03-11 | 2020-12-16 | 国立大学法人 岡山大学 | インフルエンザ治療剤 |
CN106146657B (zh) * | 2016-07-12 | 2020-07-17 | 晋明(天津)生物医药技术开发有限公司 | 广谱结合流感病毒a的重组抗体片段及其制备方法与应用 |
WO2018030777A1 (fr) * | 2016-08-10 | 2018-02-15 | ㈜셀트리온 | Préparation pharmaceutique liquide stable pour anticorps anti-virus de la grippe |
WO2018038096A1 (fr) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | Anticorps monoclonal ou fragment de liaison à l'antigène de celui-ci, et son utilisation |
CN107011436B (zh) * | 2017-04-10 | 2019-02-26 | 江苏省疾病预防控制中心 | 抗h7n9病毒的单克隆抗体 |
JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザhaスプリットワクチンの製造方法 |
CN108299316B (zh) * | 2018-01-24 | 2020-03-31 | 山东大学 | 一种抗流感病毒化合物及其制备方法和应用 |
CA3088194A1 (fr) * | 2018-01-26 | 2019-08-01 | Regeneron Pharmaceuticals, Inc. | Anticorps humains contre l'hemagglutinine de la grippe |
CN108640981A (zh) * | 2018-04-25 | 2018-10-12 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | H7n9亚型流感病毒重组蛋白及病毒疫苗 |
TW202011986A (zh) | 2018-07-23 | 2020-04-01 | 公益財團法人日本健康科學振興財團 | 包含流感疫苗之組合物 |
KR20200060969A (ko) * | 2018-11-23 | 2020-06-02 | (주)셀트리온 | 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법 |
US20220152191A1 (en) | 2019-03-04 | 2022-05-19 | JAPAN as represented by DIRECTOR GENERAL of National lnstitute of lnfectious Diseases | Method for preparing influenza ha split vaccine |
KR102218980B1 (ko) * | 2019-09-18 | 2021-02-23 | 한국생명공학연구원 | 오셀타미비르 내성 인플루엔자 바이러스에 대한 항체 |
KR102373670B1 (ko) * | 2019-09-30 | 2022-03-14 | 중앙대학교 산학협력단 | 신종 인플루엔자 바이러스에 고특이적 고선택적 결합이 가능한 펩타이드 리셉터 및 그를 이용한 바이러스 검출용 바이오칩의 제작방법 |
WO2021142256A2 (fr) * | 2020-01-10 | 2021-07-15 | University Of Georgia Research Foundation, Inc. | Antigènes viraux à large spectre de réaction tels que des immunogènes, leurs compositions et méthodes d'utilisation |
KR20220139244A (ko) * | 2021-04-07 | 2022-10-14 | (주)셀트리온 | 2 이상의 사스-코로나바이러스-2 중화 결합 분자를 포함하는 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278083B2 (en) * | 2004-03-22 | 2012-10-02 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inactivated influenza virus compositions |
KR20100115346A (ko) * | 2007-12-06 | 2010-10-27 | 다나-파버 캔서 인스티튜트 인크. | 인플루엔자 바이러스에 대한 항체 및 그의 이용 방법 |
KR101005967B1 (ko) | 2008-04-12 | 2011-01-05 | (주)셀트리온 | 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포 |
MX2011000768A (es) * | 2008-07-25 | 2011-10-05 | Inst Research In Biomedicine | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. |
WO2010047509A2 (fr) * | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | Anticorps dirigé contre le dr5 présentant une meilleure affinité et une meilleure stabilité, et composition destinée a prévenir ou traiter le cancer et contenant cet anticorps |
WO2010130636A1 (fr) * | 2009-05-11 | 2010-11-18 | Crucell Holland B.V. | Molécules de liaison humaines pouvant neutraliser le virus de la grippe h3n2 et leurs utilisations |
KR101161810B1 (ko) | 2009-08-21 | 2012-07-03 | 주식회사 효성 | 태양전지의 선택적 에미터 형성방법 및 그 태양전지 제조방법 |
BR112012018458A2 (pt) | 2010-01-26 | 2018-07-10 | Nipd Genetics Ltd | métodos e composições para diagnóstico pré-natal não invasivo de aneuploidias fetais |
CN102791734B (zh) * | 2010-03-08 | 2014-10-15 | 赛特瑞恩股份有限公司 | 源自人b细胞且具有抗甲型流感病毒的中和活性的人单克隆抗体 |
CN102958539B (zh) | 2010-03-26 | 2015-07-01 | 泼莫纳搜索有限公司 | 能够识别血凝素干区上的杂亚型中和表位的IgG同种型全长免疫球蛋白和其作为抗-流感药物的应用 |
WO2011123495A1 (fr) * | 2010-03-30 | 2011-10-06 | Mount Sinai School Of Medicine | Vaccins contre le virus de la grippe et utilisations associées |
BR112014000263B1 (pt) * | 2011-07-14 | 2022-01-18 | Janssen Vaccines & Prevention B.V. | Anticorpo isolado capaz de se ligar especificamente à proteína hemaglutinina (ha) dos subtipos de vírus influenza b, e, composição farmacêutica que o compreende |
HUE044089T2 (hu) * | 2011-07-18 | 2019-09-30 | Inst Res Biomedicine | Neutralizáló anti-influenza A antitestek és alkalmazásaik |
CA2850720C (fr) * | 2011-09-30 | 2016-03-29 | Celltrion Inc. | Molecule de liaison a activite de neutralisation de virus de la grippe a produite a partir de lymphocyte b humain |
US9834594B2 (en) * | 2012-09-07 | 2017-12-05 | Celltrion, Inc. | Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses |
-
2013
- 2013-12-02 KR KR1020130148247A patent/KR20140118682A/ko unknown
-
2014
- 2014-03-28 EP EP14774436.1A patent/EP3011968B1/fr active Active
- 2014-03-28 WO PCT/KR2014/002691 patent/WO2014158001A1/fr active Application Filing
- 2014-03-28 AU AU2014244668A patent/AU2014244668B2/en active Active
- 2014-03-28 JP JP2016505410A patent/JP6072348B2/ja active Active
- 2014-03-28 EA EA201500854A patent/EA030447B1/ru not_active IP Right Cessation
- 2014-03-28 CN CN201480018932.7A patent/CN105338994B/zh active Active
- 2014-03-28 KR KR1020140036601A patent/KR101681550B1/ko active IP Right Grant
- 2014-03-28 US US14/780,682 patent/US10703802B2/en active Active
- 2014-03-28 MX MX2015013291A patent/MX364312B/es active IP Right Grant
- 2014-03-28 ES ES14774436T patent/ES2831802T3/es active Active
- 2014-03-28 CA CA2902147A patent/CA2902147C/fr active Active
-
2015
- 2015-10-06 IL IL241881A patent/IL241881B/en active IP Right Grant
-
2016
- 2016-08-31 KR KR1020160112156A patent/KR102255099B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP6072348B2 (ja) | 2017-02-01 |
MX2015013291A (es) | 2015-12-15 |
CA2902147A1 (fr) | 2014-10-02 |
EA201500854A1 (ru) | 2015-12-30 |
EP3011968A1 (fr) | 2016-04-27 |
KR20160115875A (ko) | 2016-10-06 |
IL241881B (en) | 2021-03-25 |
US10703802B2 (en) | 2020-07-07 |
WO2014158001A1 (fr) | 2014-10-02 |
KR20140118682A (ko) | 2014-10-08 |
KR101681550B1 (ko) | 2016-12-01 |
CA2902147C (fr) | 2020-02-11 |
US20160052997A1 (en) | 2016-02-25 |
KR20140119641A (ko) | 2014-10-10 |
EP3011968B1 (fr) | 2020-08-12 |
EP3011968A4 (fr) | 2016-11-02 |
ES2831802T3 (es) | 2021-06-09 |
AU2014244668A1 (en) | 2015-10-01 |
CN105338994B (zh) | 2018-11-27 |
EA030447B1 (ru) | 2018-08-31 |
JP2016516090A (ja) | 2016-06-02 |
KR102255099B1 (ko) | 2021-05-25 |
CN105338994A (zh) | 2016-02-17 |
AU2014244668B2 (en) | 2016-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015013291A (es) | Composicion que comprende al menos dos moleculas neutralizadoras-aglutinadoras del virus de influenza a. | |
EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
CL2016000493A1 (es) | Inhibidores de polimerasa hcv. | |
PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
EA201790266A1 (ru) | Индолы для применения при инфекции, вызванной вирусом гриппа | |
CL2014003634A1 (es) | Inhibidores del virus de la hepatitis c | |
EA201790571A1 (ru) | Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа | |
EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
MY183517A (en) | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof | |
BR112016006999A2 (pt) | anticorpos neutralizantes anti-influenza a e suas utilizações | |
EA200970916A1 (ru) | Соединения 5,6-дигидро-1н-пиридин-2-она | |
MX2021004464A (es) | Compuestos de tiazolida para el tratamiento de infecciones virales. | |
EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
JO3281B1 (ar) | مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي | |
EA201891576A1 (ru) | Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа | |
EA201892246A1 (ru) | Производные аминотиазола, полученные в качестве противовирусных средств | |
BR112018073944A2 (pt) | uso de uma composição. | |
CL2016000300A1 (es) | Métodos terapéuticos | |
MX2016001855A (es) | Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |